Influx Health.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

Which are the latest news on Influx Health.?

Why is Influx Healthtech Ltd falling/rising?

As of 10-Apr, Influx Healthtech Ltd's stock price is 231.15, down 0.26%. Despite a strong performance over the past week and month, recent underperformance and a significant drop in investor participation have contributed to the current decline.

As of 10-Apr, Influx Healthtech Ltd's stock price is currently at 231.15, reflecting a decrease of 0.6, or 0.26%. Despite this decline, the stock has shown positive performance over the past week, with a return of 7.36%, outperforming the Sensex, which increased by 5.89%. Over the past month, the stock has also risen by 6.08%, while the Sensex has fallen by 0.87%. Year-to-date, Influx Healthtech has gained 2.23%, contrasting with the Sensex's decline of 7.96%.<BR><BR>However, today's performance indicates that the stock has underperformed its sector by 0.55%. Additionally, there has been a significant drop in investor participation, with the delivery volume on April 9 falling by 53.66% compared to the 5-day average. Despite trading above its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), the decline in delivery volume suggests a decrease in trading activity, which may contribute to the current price drop. Overall, while the stock has shown strong performance in the longer term, the recent underperformance and reduced investor participation are key factors in its current decline.